Orexigen Therapeutics, Inc. (NASDAQ:OREX) and its its wholly-owned subsidiary Takeda Pharmaceuticals have launched sales of Contrave extended-release tablets for chronic weight management in adults. The drug is now available by prescription in the U.S. , approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) with at least one weight-related condition. Eligible patients taking Contrave will have access to the Scale Down program, which provides mobile weight management support and Contrave Direct Save, which provides the lowest cost available with home delivery. Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) are at $4.08 within a 52-week range of $3.11 - $7.82.Lennox International Inc. (NYSE:LII), the maker of products for heating, air conditioning and refrigeration reported Q3 adjusted earnings above analysts' expectations despite a slight revenue miss, and unveiled plans for a new $450 million accelerated share-repurchase program. Lennox International Inc. (NYSE:LII) is trading in a 52-week range of $72.91 to $94.69. The company posted Q3 net income of $67.4 million, or $1.38 per diluted share, up from $64.3 million, or $1.27 per diluted share, a year earlier. Adjusted earnings from continuing operations were $1.44 per share in the latest quarter, up from $1.30 per share a year earlier and above the $1.41 per share expected on average by analysts polled by Capital IQ.Net sales rose to $898.4 million from $868 million a year earlier, but missed analysts' mean estimate of $909.5 million. The company noted revenue in its residential business climbed 7% despite a negative impact from cooler summer weather than in the year-earlier period. For 2014, the company reiterated its outlook for revenue growth of 5% to 7% and adjusted EPS from continuing operations of $4.30 to $4.50. Analysts recently were projecting a 4.9% increase in revenue to $3.36 billion, and adjusted EPS from continuing operations of $4.37.Scotts Miracle-Gro Co (NYSE:SMG) said Monday its subsidiary EG Systems, doing business as Scotts Lawn Service, has acquired Action Pest Control Inc. Scotts said it is the second-largest lawn service company in the U.S. and that Action is one of the largest pest-control companies in the U.S. Midwest. The deal is expected to close by January. Scotts has been operating a pest-control business in Florida. This acquisition is the company's move to expand in the industry, and Scotts said it expects the business to add annual sales accretive to fiscal 2015 approaching $15 million. Scotts Miracle-Gro Co (NYSE:SMG) has traded in a range from $52.38 to $63.96 a share in the past 52 weeks.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
